Bio

Dr. Klumpp holds a diploma degree in biology from the Technical University Darmstadt, Germany, and a PhD in virology. He has worked at Wellcome Research Laboratories, Beckenham, Kent, U.K., at the European Molecular Biology Laboratories (EMBL), Heidelberg, Germany, and at the EMBL in Grenoble, France. From 2013 until present, Vice President of Discovery Research at Novira Therapeutics, Inc. Prior to joining Novira, Dr. Klumpp led research and development activities in the field of viral diseases for more than 15 years at Roche Palo Alto LLC, most recently as Vice President, Head of HCV Clinical Virology & Viral Biochemistry. Prior to Roche, he worked as a research assistant at GlaxoWellcome Research and Development (Stevenage, UK). Dr. Klumpp worked extensively in R&D collaborations with external partner companies and academic laboratories. He was responsible for the discovery and transition into clinical development of a number of new leads and drug candidates for treatment of acute and chronic viral diseases, including influenza, hepatitis C, HBV, Dengue and HIV. In addition, he supported the clinical development of antiviral drugs such as Tamiflu for the treatment and prophylaxis of influenza virus infection and Balapiravir, Mericitabine and Danoprevir, new antiviral agents for treatment of HCV infection. Dr. Klumpp serves as a Member of Scientific Advisory Board at Savira Pharmaceuticals GmbH and Vice President of discovery and development at Novira Therapeutics Inc.